8-K filed Aug 4, 2026 at 07:30 ET
Palvella Therapeutics reported Q2 2026 results with a net loss of $1.52 per share, missing the consensus estimate of $-1.15 by 32%. The company is a pre-revenue clinical-stage biotech, so the EPS miss is a mechanical artifact of increased R&D spending and share dilution from the February 2026 equity raise, not a business deterioration signal. The key catalyst is the ongoing rolling NDA submission for QTORIN rapamycin in microcystic lymphatic malformations, which remains on track for completion in H2 2026, with a potential U.S. launch in H1 2027. The company has a strong cash position of $250.6M, funding operations and launch preparations through 2027.